Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-19 · accession 0001831216-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | 2025-12-19 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | G - Gift | $0.00 | -9,000 | 542.9K | -2% | $0 | |
| M | 2025-12-23 | 2025-12-19 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $30.46 | -51.0K | 601.7K | -8% | -$1.55M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-19 | G | D | 9,000 | $0.00 | 542,881 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-19 | S | D | 6,046 | $31.39 | 551,881 | D | — | — | (F5) The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2025-12-19 | S | D | 43,729 | $30.40 | 557,927 | D | — | — | (F4) The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided |
| 4 | Common | Common Stock | 2025-12-19 | S | D | 1,225 | $28.08 | 601,656 | D | — | — | (F1) The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. (F2) On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4. (F3) Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. |